Protocols for the Provision of Cross-Gender Hormone Therapy

2012 Revision
Callen-Lorde Protocols for the Provision of Cross-Gender Hormone Therapy

Disclaimer

1. **Disclaimer as to Protocols.** The attached protocols, including all introductory materials and appendices, have been developed by and constitute the guidelines used by Callen-Lorde Community Health Center’s medical and mental health providers providing primary care to transgender patients receiving hormone therapy. The protocols are guidelines only. They reflect our review of the available medical literature and our experience in providing this therapy, but are by no means definitive. They are not the result of scientific studies or clinical trials, and there are no medications that are FDA approved for cross-gender hormone therapy. For all these reasons, no representations are made as to the propriety of their use in specific cases, and they may not be substituted for sound clinical judgment by the treating clinician.

2. **Additional Disclaimer as to Informed Consents.** The informed consent documents attached to the Protocols are provided only as examples. NO representations are made as to their applicability to or legal sufficiency for your agency. Accordingly, these documents should not be used by you without professional legal advice.

3. **Limitations on Distribution.** These documents are for the use only of the specific individual or entity to which they are addressed. If you receive a request from another party for a copy of these documents, please do not distribute them directly. Instead, please refer the request to Attn: Transgender Protocol Requests, Callen-Lorde Community Health Center, 356 West 18 Street, New York, New York 10011 or at 212-271-7200, for response.
Callen-Lorde Protocols for the Provision of Cross-Gender Hormone Therapy

General Philosophy and Vision

The Callen-Lorde Community Health Center provides trans-affirmative health care by emphasizing partnership, education, and self-determination. We view treatment as a cooperative effort between patient and provider. We strive to establish relationships with patients in which they are the primary decision makers about their care, and we serve as their partners in promoting health. This partnership supports the patient's ongoing understanding of the risks and benefits of hormone therapy. By providing thorough education around hormones and general health, we also aim to enhance a patient's ability to make informed decisions about all aspects of their health. We believe patients who are well informed have a right to make their own decisions.

Callen-Lorde acknowledges that individuals of transgender experience have traditionally met discrimination in health care settings. We seek to provide trans-affirmative health care and strive to engage patients who would otherwise be alienated from the medical system or not get medical care at all. The mission of Transgender Health Services at Callen-Lorde is to provide comprehensive quality services to our patients of diverse gender identity and expression.

Callen-Lorde realizes that health care institutions discriminate against people of transgender experience by not conducting adequate scientific research on transgender health. We developed our protocols by compiling the collective knowledge of clinicians, patients, members of the transgender community, and related scientific studies. They are offered as guidelines for primary care for patients of transgender experience receiving hormone therapy. These guidelines should be seen as a starting point from which the patient and provider can arrive at a care plan appropriate to the patient's needs.
Callen-Lorde Protocols for the Provision of Cross-Gender Hormone Therapy

Guide to Using the Protocol

A Note on Age and Informed Consent

These protocols were written for use in patients 18 years of age or older. These protocols were not written with the specific endocrinological and psychosocial needs of younger patients in mind, nor do they address the legally complex nature of obtaining informed consent in minors. Therefore, these protocols should not be used to provide cross-gender hormone therapy to a younger age group.

Hormones can be provided to patients over the age of 18 who cannot provide informed consent on their own, through the consent of a legal or court-appointed guardian.

A Note on the Specific Timing of the Interventions

We understand that every clinical setting operates a little bit differently and changes over time. The timing of these protocols – when appointments should be made, when bloodwork needs to be drawn in relation to appointments, etc. – was written with Callen-Lorde’s current operations in mind. When adapting these protocols to a different setting, it may be more practical to keep these general principles in mind, rather than the specific timing:

1. When starting a new medication, start at half-dose.
2. Reassess the patient one month after initial prescription with bloodwork, history and physical evaluation before increasing the medication to full dose (prescribe only enough for one month).
3. Reassess the patient one month later at full dose.
4. Reassess the patient three months later.
5. Reassess the patient every six months to one year.
6. Maintain a harm reduction approach and be open to negotiation at every step.
Callen-Lorde Protocols for the Provision of
Cross-Gender Hormone Therapy

Acknowledgements

The following Callen-Lorde Community Health Center staff members and external experts assisted in the
2012 revision of the protocols:

Gal Mayer, MD
Anita Radix, MD, MPH
Katie Douglass, LCSW-R
Anthony Vavasis, MD
Ronica Mukerjee, NP
Susan Weiss NP
Juliet Widoff, MD
Manel Silva, MD

Medical Director
Director of Research and Education
Director of Mental Health and Social Services
Clinical Director of Medical Services
Medical Provider
Clinical Director of HIV Services
Medical Provider
Clinical Director of Adolescent Health

External Expert Panel Members:
Renato Barucco, MS
Jeff Birnbaum, MD
Adrian Costello, LMSW
Maddie Deutsch, MD
Kelly Ducheny, PsyD
Deborah Dunn, PAC, MBA
Elaine Dutton, LSW
Justus Eisfeld
A. D. Fernandez, MD, FAAP
Donna Futterman, MD
Dawn Harbatkin, MD
Ruben Hopwood, M.Div.
Peter Meacher, MD
Robert Murayama, MD, MPH
Tonia Poteat, PhD, MPH, PA-C
Alan Shapiro, MD
John Steever, MD

Community Healthcare Network, NY
SUNY Downstate's HEAT Program, NY
Community Healthcare Network, NY
L.A. Gay & Lesbian Center, CA
Howard Brown Health Center, IL
Chase Brexton Health Services, MD
Mazzoni Center, PA
Global Action for Trans* Equality, NY
Adolescent AIDS Program, NY
Adolescent AIDS Program, NY
Lyon-Martin Health Services, CA
Fenway Health, MA
Montefiore's Bronx Center for Children and Families, NY
APICHA Community Health Center, NY
Medical Provider
Children’s Hospital at Montefiore, NY
Mt.Sinai Adolescent Health Center, NY
Callen-Lorde Protocols for the Provision of Cross-Gender Hormone Therapy

Table of Contents

GENERAL PHILOSOPHY AND VISION...........................................................................2
GUIDE TO USING THE PROTOCOL .........................................................................3
ACKNOWLEDGEMENTS...............................................................................................3
CLINICAL VISIT PROTOCOL FOR THE INITIATION OF CROSS-GENDER HORMONE THERAPY ..........6
SPECIAL CONSIDERATIONS:
  Hormone-Experience Clients.............................................................................23
  Client Who Have Undergone Gonadectomy .....................................................23
  Clients over 45 Years/Smokers ......................................................................23
  HIV Infection.....................................................................................................23
REFERENCES.............................................................................................................24
APPENDIX 1  CONSENT FORMS
  For Women of Transgender Experience ............................................................27
  For Men of Transgender Experience ................................................................29
APPENDIX 2  TRANSGENDER HEALTH RESOURCE GUIDE .................................................31
APPENDIX 3  MANAGING COMORBIDITIES
  Active Psychosis ..................................................................................................32
  Cigarette Smoking ...............................................................................................32
  Coronary Artery Disease ....................................................................................32
  Dementia .............................................................................................................32
  History of Deep Venous Thrombosis, Pulmonary Embolism, or Embolic Stroke ....32
  Homicidal/Suicidal Ideation/Attempts.................................................................33
  Liver Disease .......................................................................................................33
  Pituitary Adenoma ..............................................................................................33
  Uncontrolled Diabetes .........................................................................................33
  Uncontrolled Hypertension ...............................................................................33
  Substance Use ......................................................................................................33
  HIV Infection .......................................................................................................33
APPENDIX 4  MANAGING LABORATORY ABNORMALITIES
  Anemia ..................................................................................................................35
  Erythrocytosis .....................................................................................................35
  Elevated Prolactin Level ......................................................................................35
  Elevated Transaminases (LFTs) ........................................................................35
APPENDIX 5  TABLES OF MEDICATIONS AND THEIR EFFECTS
  Table 1: “Feminizing” Regimens ........................................................................37
  Table 2: Anti-Androgens ....................................................................................38
  Table 3: “Masculinizing” Regimens .................................................................40
  Table 4A: Masculinizing Effects in FTM Clients Receiving Testosterone .........41
  Table 4B: Feminizing Effects in MTF Clients Receiving Estrogen and Anti-Androgen ..41
Clinical Visit Protocol for
The Initiation of
Cross-Gender
Hormone Therapy
<table>
<thead>
<tr>
<th>Visit 1</th>
<th>Initial Medical Intake</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Provider</strong></td>
<td>Medical Provider</td>
</tr>
<tr>
<td><strong>Goals of the Session</strong></td>
<td>To introduce patients to the Callen-Lorde Transgender health services</td>
</tr>
<tr>
<td></td>
<td>To collect baseline medical information</td>
</tr>
<tr>
<td></td>
<td>To begin hormone therapy assessment</td>
</tr>
<tr>
<td></td>
<td>To engage patients in a comprehensive primary care system</td>
</tr>
</tbody>
</table>

1. Introduce patient to the Callen-Lorde Transgender Health Services
2. Provide and explain [Transgender Health Resources Packet](http://callen-lorde.org/pdf/NYC%20Metro%20TGNC%20Resources.pdf), available on Callen-Lorde’s Transgender Health Services webpage.
3. Discuss hormones, risks and benefits, and elicit patient’s expectations
4. Discuss possible diagnostic codes:
   - Trans-Sexualism - unspecified sexual history – 302.50 (ICD-9)
   - Unspecified Endocrine Disorder – 259.9 (ICD-9)
   - Unspecified Endocrine Disorder – E34.9 (ICD-10)
5. Collect a complete medical history, including medical conditions that can be exacerbated by Cross Gender Hormone Therapy:
   - Coronary Artery Disease
   - Deep Vein Thrombosis/Pulmonary Embolus
   - Embolic stroke
   - Liver disease
   - Pituitary adenoma
   - Uncontrolled Hypertension
   - Uncontrolled Diabetes
   - Breast or uterine cancer
   - Erythrocytosis
6. Assess Health Care Maintenance (HCM) and update as needed, including:
   - Tuberculosis screening (PPD status)
   - Immunization history, including Hepatitis A, Hepatitis B, Measles/Mumps/Rubella (MMR), Tetanus/diphtheria (Td/Tdap), influenza, pneumococcus, Human Papillomavirus (HPV)
   - Breast/chest Self-Exam
   - Testicular Self-Exam
   - Pelvic exam
   - HIV status and risk assessment
   - If over 50, need for colon cancer screening (>45 for African-American) or baseline EKG
7. Elicit mental health history including history of transgender identity, and screen for potential mental health concerns (see Appendix 3):
   - Active psychosis
   - Cognitive impairment
   - Dementia
   - Suicidal/Homicidal ideation/Attempts

8. Elicit social history:
   - Alcohol use
   - Employment history
   - History of or current domestic violence or abuse
   - Illicit drug or street hormone use
   - Living situation
   - Sexual history
   - Gender identity history and prior transgender care
   - Social supports
   - Tobacco use
   - Silicone use

9. Elicit family history:
   - Cancer (i.e., breast, colon, ovarian, prostate)
   - Diabetes
   - Heart disease
   - Hypertension
   - Liver disease

10. Elicit medications:
    - Prescribed
    - Herbal
    - Over the counter
    - Street
    - Supplements
    - Prior hormone use

11. Screen for allergies.

12. Draw labs:
    - Complete Blood Count
    - Comprehensive Metabolic Panel (electrolytes, liver enzymes, lipids)
    - Hepatitis A, B and C panel
    - Syphilis screening (RPR)

**Note:** Some guidelines recommend checking estradiol and testosterone levels at baseline and throughout the monitoring of estrogen therapy. We have not found a clinical use for routine hormone levels that justifies the expense. However, we recognize that individual providers may adjust their prescribing and monitoring practices as needed to comply with guidelines or when guided by patient need.
13. If HIV status unknown, offer HIV testing.

14. If indicated, ask patient for records of relevant previous or current medical care, including HIV, mental health, and/or substance use/abuse treatment, as applicable.

15. Arrange follow up:
   - Supportive counseling and education
   - Medical visit

**Note:** As with all primary care patients, Primary Care Provider (PCP) can make direct referral to psychiatry, Mental Health, HIV counseling and testing, care coordination, or case management if there are any concerns
Visit 2 Hormone Counseling & Education Session

<table>
<thead>
<tr>
<th>Provider</th>
<th>Mental Health Provider, RN or Medical Provider</th>
</tr>
</thead>
</table>

**Goals of the Session**

- To counsel and assess patient ability to provide informed consent to Cross-Gender Hormone Therapy
- To assess and initiate management of mental health complaints that might be adversely affected by Cross-Gender Hormone Therapy
- To assess additional biopsychosocial needs of patient and offer related referrals/resources as indicated and/or requested

1. **Introduce purpose of Hormone Counseling & Education Session**
   - Counsel about the known risks and benefits of exogenous hormone therapy and confirm patient can provide informed consent to Cross-Gender Hormone Therapy
   - Assess acute, active mental health complaints that may be adversely affected by Cross-Gender Hormone Therapy
   - Assess and provide psychosocial supports and referrals as indicated.
   - Communicate assessment and findings to the medical provider who will be prescribing Cross-Gender Hormone Therapy.

2. **Obtain informed consent to Cross-Gender Hormone Therapy**
   - Assess that the patient’s goals and understanding of Cross-Gender Hormone Therapy match the general nature and purpose of Cross-Gender Hormone Therapy
   - Assess patient’s understanding of the physical, mental health, and social benefits and risks of Cross-Gender Hormone Therapy
   - When applicable discuss alternatives to Cross-Gender Hormone Therapy.

3. **Assess patient’s day-to-day mood/mental health.**
   - Counsel patient on the psychoactive effects of hormones:
     - Some mood/mental health problems such as depression and anxiety may be addressed by hormones, some symptoms are not
     - Some mood/mental health problems, including depression, anxiety and psychosis, may be exacerbated by hormones.
   - Gather information about patient’s mood/mental health for the purpose of forecasting symptoms that may be intensified by Cross-Gender Hormone Therapy:
     - If patient has untreated, non-acute symptoms, offer and refer patient to supportive mental health services (such as psychotherapy or psychiatry)
     - If patient has acute, untreated mood problems, discuss ways Cross-Gender Hormone Therapy and mood problems can be managed safely. Guide patient to discuss these symptoms with the medical provider who will be prescribing Cross-Gender Hormone Therapy.
4. Explore patient’s social transition needs such as peer support, psychotherapy, identifying documentation changes, care coordination, and legal advocacy
   - As indicated, refer patient to internal and external resources, including Transgender Care Coordinator.

**Note:** *Engagement in mental health care is not a requirement for hormone initiation.*

5. Elicit any additional questions the patient may have about Callen-Lorde’s services, and/or physical or social transition.
   - If patient intends to pursue gender confirming surgery, discuss ways to access surgical referrals as well as documentation required for surgery.

6. Arrange an additional Hormone Counseling & Education Session visit if:
   - Patient is unable to establish informed consent in the first session
   - Patient is interested in accessing additional support and/or counseling around Cross-Gender Hormone Therapy

7. Document visit in electronic health record, including overall assessment of patient’s ability to provide informed consent and any relative or absolute contraindications elicited during evaluation. Communicate directly with the prescribing provider about any serious concerns.
Visit 3  Medical Visit

Provider  Medical Provider

Goals of the Session  
To complete medical/psychosocial assessment from Visit 1

To initiate hormone therapy

Note: Depending on how much was covered in Visit 1, Visit 3 may cover more ground than is feasible in one appointment. If necessary to cover all the following elements, Visit 3 may be split into two appointments. Importantly, hormone treatment should not be initiated in a hormone-naïve patient until all the elements in Visits 1-3 are completed.

1. Continue medical/psychosocial work-up from visit 1.

2. Review records from prior Primary Care Provider, if obtained.

3. Perform a complete physical exam.

Note: The patient may postpone or refuse breast/chest or genital exam. If the patient refuses, renegotiate the time at which the exam will be done

4. Review lab results and discuss implications of abnormal findings.

5. Continue Health Care Maintenance assessment from Visit 1.

6. If indicated, perform tuberculosis screening (PPD).

7. Give vaccines (Hepatitis A/B, HPV, etc) if indicated and desired.

8. Discuss smoking cessation if appropriate.

9. Arrange follow up medical visit within 4 weeks.

10. Discuss treatment plan.

11. Review the hormone therapy consent forms (see Appendix 1).

12. Document formal assessment of capacity to give consent in chart:
   - Ability to communicate choice
   - Comprehension of clinical situation
   - Understanding of alternatives (hormones, surgery, no treatment), benefits, and risks

13. If patient has capacity, have patient sign the informed consent for hormone therapy.

14. If patient signs informed consent, document that patient can begin hormone therapy.
15. Review Appendix 5 for available medications, potential side effects, and timeline of expected physical changes.

16. Discuss with the patient the preferred route of hormones and prescribe one month of the appropriate regimen:

A. For Transgender women (MTF): The usual regimen is an estrogen + anti-androgen.

### ESTROGENS:
Prescribe one month of **ONE** of the following hormones:

#### Preferred Regimen:

<table>
<thead>
<tr>
<th>Oral Estrogen</th>
<th>Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol (Estrace)</td>
<td>1.0mg</td>
<td>Oral, twice daily</td>
<td>60 tablets</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Injectable Estrogen</th>
<th>Dose Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol Cypionate 5mg/ml 0.5cc (2.5mg)</td>
<td>Intramuscular, every two weeks</td>
<td>1.0cc</td>
<td>0</td>
</tr>
<tr>
<td>Estradiol Valerate 20mg/ml 0.5cc (10mg)</td>
<td>Intramuscular, every two weeks</td>
<td>1.0cc</td>
<td>0</td>
</tr>
</tbody>
</table>

#### Alternate Regimen:

<table>
<thead>
<tr>
<th>Oral Estrogen</th>
<th>Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premarin</td>
<td>1.25mg</td>
<td>Oral, twice daily</td>
<td>60 tablets</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Transdermal Estrogen</th>
<th>Dose Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol Patch *</td>
<td>0.05-0.1 mg One patch topically, twice weekly</td>
<td>8 patches</td>
<td>0</td>
</tr>
</tbody>
</table>

* Transdermal estrogen may be preferred in some circumstances, e.g. age over 45, history of venous thromboembolic disease or cardiovascular risk factors. Although most patches are applied twice weekly, this may differ by product. Goal is to provide an initial dose of 50-100 mcg transdermal estradiol daily.

§ Some providers recommend administering oral estradiol sublingually or injectable estradiol subcutaneously.

### ANTI-ANDROGENS:
Prescribe one month of **ONE** of the following anti-androgens.

#### DHT-BLOCKERS:
Some clinicians use dihydrotestosterone blockers as a primary anti-androgen, although they are less effective than either spironolactone or flutamide. DHT-Blockers may also be added to traditional anti-androgens to minimize androgenic hair loss.

#### Preferred Regimen:

<table>
<thead>
<tr>
<th>Oral Anti-Androgen</th>
<th>Daily Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spironolactone</td>
<td>100mg</td>
<td>Oral, single or divided doses daily</td>
<td>1 month</td>
<td>0</td>
</tr>
</tbody>
</table>

#### Alternate Regimen:

<table>
<thead>
<tr>
<th>Oral Anti-Androgen</th>
<th>Daily Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flutamide (Eulexin)</td>
<td>125 mg</td>
<td>Oral, twice daily</td>
<td>60 tablets</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oral DHT-Blockers</th>
<th>Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finasteride (Proscar)</td>
<td>5mg</td>
<td>Oral, once daily</td>
<td>30 tablets</td>
<td>0</td>
</tr>
<tr>
<td>Dutasteride (Avodart)</td>
<td>0.5mg</td>
<td>Oral, once daily</td>
<td>30 tablets</td>
<td>0</td>
</tr>
</tbody>
</table>
PROGESTERONE: Progesterone is not recommended as a part of the hormone regimen. It has not been shown to increase breast size, and may contribute to adverse outcomes. See Appendix 5 for dosing and adverse effects.

B. For Transgender men (FTM): The usual regimen is testosterone.

TESTOSTERONE: Prescribe one month of ONE of the following hormones*:

Preferred Regimen:

<table>
<thead>
<tr>
<th>Injectable Testosterone</th>
<th>Dose</th>
<th>Route &amp; Frequency§</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone cypionate or enanthate 200mg/ml§§</td>
<td>0.5cc (100mg)</td>
<td>Intramuscular, every two weeks</td>
<td>1cc</td>
<td>0</td>
</tr>
</tbody>
</table>

Alternate Regimen:

<table>
<thead>
<tr>
<th>Transdermal Testosterone</th>
<th>Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone gel 1% (Androgel, Testim)**</td>
<td>2.5-5mg</td>
<td>One packet topically, daily</td>
<td>30 packets</td>
<td>0</td>
</tr>
<tr>
<td>Testosterone patch (Androderm)</td>
<td>5mg</td>
<td>One patch topically, daily</td>
<td>30 patches</td>
<td>0</td>
</tr>
</tbody>
</table>

* A dihydrotestosterone blocker (e.g. Finasteride) at the usual male doses may be used in addition to testosterone to reduce androgenic hair loss.

**Low-dose transdermal testosterone may be insufficient to stop menses, consider addition of depot medroxyprogesterone (DepoProvera).

§ Some providers recommend administering injectable testosterone subcutaneously.

§§ Important: Commercially available testosterone cypionate is usually suspended in cottonseed oil. Testosterone enanthate is usually suspended in sesame oil. Enquire about allergies before prescribing these medications.

Agents not available in the USA (See Appendix 5)
Some clients may obtain hormones and anti-androgens from international pharmacies.

FTM:
- Testosterone undecanoate (oral) 160–240 mg/d
- Dihydrotestosterone 10% cream applied topically (to clitoris) 20mg three times daily. (Prescribed by some surgeons 3 months before metoidioplasty to increase clitoral size; however, insufficient data on efficacy.)

MTF:
- Cyproterone Acetate 50-150 mg/day oral (an anti-androgen)

17. Give appropriate vaccinations

18. Order lab work for next medical visit (schedule 4 weeks after starting hormones)
- Liver enzymes
- Electrolytes, if taking spironolactone
- Complete blood count, if taking flutamide
19. Arrange follow up

- If patient is taking injectable hormones and is not returning on the same day for the injection, first available nursing visit after filling prescription.
- Nursing visit 2 weeks after first injection (if using injectable)
- Nursing visit 4 weeks after first injection (if using injectable)
- Medical visit in 5 weeks (all clients)
Visit 4

Nursing Visit

Provider
Nursing Provider

Goals of the Session
To provide patient with first injection of hormone therapy

1. Ask patient preferred method of injection: self-injection, injection by a significant other, friend, family or ally (SOFFA) or by nurse at Callen-Lorde.

2. If patient prefers nursing staff to inject, administer:

**MTF clients**

<table>
<thead>
<tr>
<th>Injectable Estrogen</th>
<th>Dose</th>
<th>Route &amp; Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol Cypionate 5mg/ml</td>
<td>0.5cc (2.5mg)</td>
<td>Intramuscular, every two weeks</td>
</tr>
<tr>
<td>Estradiol Valerate 20mg/ml</td>
<td>0.5cc (10mg)</td>
<td>Intramuscular, every two weeks</td>
</tr>
</tbody>
</table>

**FTM clients**

<table>
<thead>
<tr>
<th>Injectable Testosterone</th>
<th>Dose</th>
<th>Route &amp; Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone cypionate or enanthate 200mg/ml</td>
<td>0.5cc (100mg)</td>
<td>Intramuscular, every two weeks</td>
</tr>
</tbody>
</table>

3. If the patient chooses self-injection or by a SOFFA and is unfamiliar with self-injection, initiate teaching of safe injection technique

4. If the patient or a SOFFA is familiar with self-injection, observe the injection being administered by the designated person and provide feedback. If the technique is sound, document approval for self-injection in the chart. If technique needs improvement, offer instruction.

5. Arrange follow up Nursing Visit every 2 weeks to continue teaching of safe injection technique to patient or SOFFA.

6. Arrange for laboratory testing 4 weeks after initiation of hormones:
   - Liver enzymes
   - Electrolytes, if taking spironolactone
   - Complete blood count, if taking flutamide
Visit 5 – 4 weeks after starting half-dose hormones

Medical Visit

<table>
<thead>
<tr>
<th>Provider</th>
<th>Medical Provider and Nursing Provider</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goals of the Session</td>
<td>To perform initial assessment after the initiation of hormone therapy</td>
</tr>
<tr>
<td></td>
<td>To continue hormone therapy</td>
</tr>
<tr>
<td></td>
<td>To continue the provision of primary care</td>
</tr>
</tbody>
</table>

**Nursing Provider:**

1. Check the patient’s vital signs, including blood pressure.
2. Proceed with hormone injection after Medical Provider has reviewed the laboratory results and authorized continuation of the treatment.
3. If patient has chosen injectable hormones and is due for an injection:
   - Ask if the patient is receiving injections from self or a SOFFA. If so, observe the injection technique.
   - If the technique is sound, document approval for self-injection in the chart.
   - If the technique needs improvement:
     - Offer instruction and support.
     - Schedule bi-weekly nursing appointments for further teaching and injections until the nursing provider assesses that the patient or SOFFA has learned the proper technique and can safely inject without supervision.

**Medical Provider:**

4. Take history with focus on
   - Patient's tolerance of hormones and anti-androgens
   - Any side effects patient may be experiencing
   - MTF client: Cessation of erections
   - FTM client: Cessation of menses
5. Perform physical exam, including blood pressure.
6. Review lab results and discuss implications of abnormal findings.
7. Increase the dosage of hormones as follows and prescribe one month of:

A. For Transgender women (MTF):

**ESTROGENS:** Prescribe one month of **ONE** of the following hormones:

*Preferred Regimen:*

<table>
<thead>
<tr>
<th>Oral Estrogen</th>
<th>Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol (Estrace)</td>
<td>2.0mg</td>
<td>Oral, twice daily</td>
<td>60 tablets</td>
<td>0</td>
</tr>
</tbody>
</table>

*Injectable Estrogen:*

<table>
<thead>
<tr>
<th>Injectable Estrogen</th>
<th>Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol Cypionate 5mg/ml</td>
<td>1.0cc (2.5mg)</td>
<td>Intramuscular, every two weeks</td>
<td>5.0cc</td>
<td>0</td>
</tr>
<tr>
<td>Estradiol Valerate 20mg/ml</td>
<td>1.0cc (10mg)</td>
<td>Intramuscular, every two weeks</td>
<td>5.0cc</td>
<td>0</td>
</tr>
</tbody>
</table>

*Alternate Regimen:*

<table>
<thead>
<tr>
<th>Oral Estrogen</th>
<th>Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premarin</td>
<td>1.25mg</td>
<td>Oral, two tablets twice daily</td>
<td>120 tablets</td>
<td>0</td>
</tr>
<tr>
<td>Transdermal Estrogen</td>
<td>Dose</td>
<td>Route &amp; Frequency</td>
<td>Amount</td>
<td>Refills</td>
</tr>
<tr>
<td>Estradiol Patch</td>
<td>0.1mg</td>
<td>Two patches topically, twice weekly</td>
<td>16 patches</td>
<td>0</td>
</tr>
</tbody>
</table>

**ANTI-ANDROGENS:** Prescribe one month of **ONE** of the following anti-androgens.

**DHT-BLOCKERS:** Some clinicians use dihydrotestosterone blockers as a primary anti-androgen, although they are less effective than either spironolactone or flutamide. DHT-Blockers may also be added to traditional anti-androgens to minimize androgenic hair loss.

*Preferred Regimen:*

<table>
<thead>
<tr>
<th>Oral Anti-Androgen</th>
<th>Daily Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spironolactone</td>
<td>200mg</td>
<td>Oral, in divided doses daily</td>
<td>1 month</td>
<td>0</td>
</tr>
</tbody>
</table>

*Alternate Regimen:*

<table>
<thead>
<tr>
<th>Oral Anti-Androgen</th>
<th>Daily Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flutamide (Eulexin)</td>
<td>125 mg</td>
<td>Oral, twice daily</td>
<td>60 tablets</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oral DHT-Blocker</th>
<th>Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finasteride (Proscar)</td>
<td>5mg</td>
<td>Oral, once daily</td>
<td>30 tablets</td>
<td>0</td>
</tr>
<tr>
<td>Dutasteride (Avodart)</td>
<td>0.5mg</td>
<td>Oral, once daily</td>
<td>30 tablets</td>
<td>0</td>
</tr>
</tbody>
</table>
B. For Transgender men (FTM):

**TESTOSTERONE:** Prescribe one month of **ONE** of the following hormones:

**Preferred Regimen:**

<table>
<thead>
<tr>
<th>Injectable Testosterone</th>
<th>Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone cypionate or enanthate 200mg/ml</td>
<td>1.0cc (200mg)</td>
<td>Intramuscular, every two weeks</td>
<td>2cc</td>
<td>0</td>
</tr>
</tbody>
</table>

**Alternate Regimen:**

<table>
<thead>
<tr>
<th>Transdermal Testosterone</th>
<th>Dose</th>
<th>Route &amp; Frequency</th>
<th>Amount</th>
<th>Refills</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone gel 1% (Androgel, Testim)</td>
<td>5mg</td>
<td>One packet topically, daily</td>
<td>30 packets</td>
<td>0</td>
</tr>
<tr>
<td>Testosterone patch (Androderm)</td>
<td>5mg</td>
<td>One patch topically, daily</td>
<td>30 patches</td>
<td>0</td>
</tr>
</tbody>
</table>

8. If the patient chose injection by herself or SOFFA and nursing approved the injection technique, prescribe:

<table>
<thead>
<tr>
<th>Equipment</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>3cc syringe</td>
<td>#10</td>
</tr>
<tr>
<td>20-22G x 1.5” needles</td>
<td>#10</td>
</tr>
<tr>
<td>Alcohol prep pads</td>
<td>#100</td>
</tr>
<tr>
<td>needle disposal (sharps) container</td>
<td>#1</td>
</tr>
</tbody>
</table>

**Note:** other needle sizes and amounts may be more appropriate for some patients depending on personal preference and whether patients use different needles for drawing the medication and injecting.

9. Order lab work for next medical visit in 4-5 weeks:
   - Liver enzymes
   - Lipids
   - Prolactin level, if MTF on estrogen
   - Electrolytes, if taking spironolactone
   - Complete blood count, if taking flutamide

10. Arrange follow up:
    - Nursing visit every 2 weeks, if requesting injections by nurse
      - If the patient chose self-injection or injection by SOFFA, observe the injection being administered by the designated person and provide feedback. If the technique is sound, document approval for self-injection in the chart. If technique needs improvement, offer instruction.
    - Medical visit in 4-5 weeks
Visit 6 - 4 weeks after starting full-dose hormones

**Medical Visit**

**Provider**
Medical and Nursing Provider

**Goals of the Session**
- To perform assessment after a change of hormone therapy
- To continue hormone therapy
- To continue the provision of primary care

**Nursing Provider:**

1. Check the patient’s vital signs, including blood pressure.
2. Proceed with hormone injection after Medical Provider has reviewed the laboratory results and authorized continuation of the treatment.
3. If patient has chosen injectable hormones and is due for an injection:
   - Ask if the patient is receiving injections from self or a SOFFA. If so, observe the injection technique. If the technique is sound, document approval for self-injection in the chart. If the technique needs improvement:
     - Offer instruction and support.
     - Schedule bi-weekly nursing appointments for further teaching and injections until the nursing provider assesses that the patient or SOFFA has learned the proper technique and can safely inject without supervision.
   - If the patient prefers nursing staff to inject, administer appropriate hormone and dose.

**Medical Provider:**

4. Take brief history with focus on:
   - Patient's tolerance of hormones and anti-androgens
   - Any side effects patient may be experiencing
   - MTF client: Cessation of erections
   - FTM client: Cessation of menses
5. Review lab results and discuss implications of abnormal findings (see Appendix 4).
6. Discuss smoking cessation if appropriate.
7. Prescribe three months of ONE of the hormones and anti-androgens as outlined in Visit 5.
8. If the patient chose injection by herself or SOFFA and nursing approved the injection technique, prescribe syringes and needles as outlined in Visit 5.
9. If the patient is receiving injections from self or SOFFA and the technique needs improvement, refer to nursing provider for further teaching and injections until the nursing provider assesses that the patient or SOFFA has learned the proper technique and can safely inject without supervision.

10. Order lab work for next visit:
   - Liver enzymes
   - Lipids
   - Prolactin level
   - Electrolytes, if taking spironolactone
   - Complete blood count, if taking flutamide

11. Arrange follow up:
   - Medical visit in 3 months
   - Lab visit one week prior to medical visit
   - Supportive counseling and education session in 1 month, if the need is identified
   - Nursing visits for injection teaching as needed
Visit 7 - 3 months after initiating hormones

Medical Visit

Provider
Medical Provider

Goals of the Session
To continue health assessment after the initiation of hormone therapy
To continue hormone therapy
To continue the provision of primary care

1. Take brief history with focus on:
   - Patient's tolerance of hormones and anti-androgens
   - Any side effects patient may be experiencing
   - How transition is going
   - Cessation of erections/cessation of menses

2. Perform brief physical exam.

3. Review lab results and discuss implications of abnormal findings.

4. Give vaccines as needed.

5. Discuss smoking cessation if appropriate.

6. Prescribe hormones, anti-androgens, syringes and needles for 6 months.

7. Order lab work for next visit:
   - Complete blood count
   - Comprehensive metabolic panel (liver enzymes, electrolytes, lipid panel)
   - Prolactin (for MTF on estrogen)

8. Arrange follow up:
   - Medical visits every 6 months with lab visits one week prior and appointments for refills as needed.
   - Supportive counseling and education sessions and psychiatric consultations offered whenever the need is identified.
   - Continue routine, age-appropriate health care maintenance, including screening for sexually transmitted diseases if appropriate.
Callen-Lorde Protocols for the Provision of Cross-Gender Hormone Therapy

Special Considerations

1. **Hormone-Experienced Clients**
   - To minimize interruption in hormonal transition, clients who have been on hormones for more than 50% of the last two years can be prescribed hormones at the end of the first intake visit, after completing the informed consent forms and having baseline laboratory tests drawn.
   - Ongoing engagement in preventive health services should be strongly encouraged.

2. **Clients who have undergone gonadectomy (removal of the testes or ovaries)**
   - Transwomen/MTF: Lower doses of estrogens are recommended, usually half of the dose used before surgery, e.g. 1-2mg estradiol daily. Anti-androgens (spironolactone) can be stopped, although clients may wish to continue dihydrotestosterone blockers if androgenic hair loss continues.
   - Transmen/FTM: Testosterone doses can be maintained at usual levels.
   - All clients: Monitor bone density, especially in clients with risk factors or who have stopped hormone therapy.

3. **Clients over 45 years/smokers**
   - Oral estrogens confer an increased risk of thromboembolic disease. Transdermal or parenteral routes are preferred over oral estrogen. Conjugated estrogen (Premarin) is not recommended.
   - Consider addition of aspirin

4. **HIV infection (see Appendix 3 - Managing Comorbidities)**
   - HIV disease is not a contraindication to hormone therapy.
   - Most antiretrovirals can be used safely although amprenavir (Agenerase) and fosamprenavir (Lexiva) are not recommended for coadministration with estrogens due to a decrease in amprenavir serum concentrations. See DHHS guidelines for updated information on drug-drug interactions.
   - Screen for osteoporosis in accordance with current prevention guidelines for HIV-infected individuals. Monitor vitamin D levels and replace if low.
   - Consider monitoring estradiol levels when initiating or changing anti-retroviral therapy.
   - Consider addition of aspirin.
References

The following are Standards of Care, Protocols and related studies that we reviewed in developing our Cross-Gender Hormone Therapy protocols:

5. The World Professional Association for Transgender Health. Standards of Care for the Health of Transsexual Transgender, and Gender Nonconforming People 7th Version | www.wpath.org
18. J W Jacobit, L J Gooren, and H M Schulte. Safety aspects of 36 months of administration of long-acting...


Callen-Lorde Protocols for the Provision of Cross-Gender Hormone Therapy

Appendix 1

CONSENT FORMS

1. For Women of Transgender Experience, Initiation of Care
2. For Men of Transgender Experience, Initiation of Care
CGHT Consent Form 1

Medical Record Number:

Date of Birth:

Patient Name:

SPECIFIC INFORMED CONSENT
FOR HORMONE THERAPY

For Women Of Transgender Experience

Initiation of Care

Cross-gender hormone therapy is an important component of transition for some transgender clients, changing secondary sex characteristics to affirm a gender presentation that is consistent with their gender identity. While there are risks associated with taking feminizing/masculinizing medications, when appropriately prescribed they can greatly improve quality of life and psychological well-being. The goal of this consent form is to review the potential risks and benefits associated with use of cross-gender hormone therapy.

A. The full medical effects and safety of hormone therapy are not fully known. Potential adverse effects may include, but are not limited to:

- Increased or decreased cholesterol and/or fats in the blood, which may increase risk for heart attack or stroke.
- Increased levels of potassium in the blood, which may cause abnormal heart rhythms.
- Increased risk of the following:
  - Blood clots, (deep venous thrombosis, pulmonary embolism);
  - Breast tumors/cancer;
  - Heart disease, arrhythmias, and stroke;
  - High blood pressure;
  - Liver inflammation;
  - Pituitary tumors (tumor of small gland in the brain which makes prolactin);
- Decreased number of red blood cells (anemia);
- Acne (if progesterone is used);
- Increased or decreased sex drive and sexual functioning;
- Psychiatric symptoms such as depression and suicidal feelings; anxiety; psychosis (disorganization and loss of touch with reality), and worsening of pre-existing psychiatric illnesses.

B. Some side effects from hormones are irreversible and can cause death.
C. The risks for some of the above adverse events may be INCREASED by
   - Pre-existing medical conditions
   - Pre-existing psychiatric conditions
   - Cigarette smoking
   - Alcohol use

D. Irreversible body changes (potential increases with length of time on hormones) resulting
   from hormone therapy may include, but are not limited to:
   - Breast growth,
   - Decreased bone density,
   - Fat redistribution,
   - Genital changes (i.e. smaller testes & penis),
   - Higher pitch of voice,
   - Infertility.

E. My signature below constitutes my acknowledgement of the following:
   - My Callen-Lorde medical provider has discussed with me the nature and purpose of
     hormone therapy; the benefits and risks, including the risk that hormone therapy may
     not accomplish the desired objective; the possible or likely consequences of hormone
     therapy; and all feasible alternative diagnostic or treatment options.
   - I have read and understand the above information regarding the hormone therapy, and
     accept the risks involved.
   - I have met with a Callen-Lorde Provider for education and support regarding
     hormone therapy.
   - I have received a list of community services and resources for people of transgender
     experience.
   - I have had sufficient opportunity to discuss my condition and treatment with the
     medical provider, nursing staff, and/or other Callen-Lorde staff, and all of my
     questions have been answered to my satisfaction.
   - I believe I have adequate knowledge on which to base an informed consent to the
     provision of hormone therapy.
   - I authorize and give my informed consent to the provision of hormone therapy.

Signature of Client ___________________________ Date ______________

Legal Name of Client (Printed) ___________________________

Signature of Witness ___________________________ Date ______________

Name of Witness (Printed) ___________________________

My medical provider is
CGHT Consent Form 2

Medical Record Number:

Date of Birth:

Patient Name:

SPECIFIC INFORMED CONSENT
FOR HORMONE THERAPY

For Men Of Transgender Experience

Initiation of Care

Cross-gender hormone therapy is an important component of transition for some transgender clients, changing secondary sex characteristics to affirm a gender presentation that is consistent with their gender identity. While there are risks associated with taking feminizing/masculinizing medications, when appropriately prescribed they can greatly improve quality of life and psychological well-being. The goal of this consent form is to review the potential risks and benefits associated with use of cross-gender hormone therapy.

A. The full medical effects and safety of hormone therapy are not fully known. Potential adverse effects may include, but are not limited to:
   - Increased cholesterol and/or fats in the blood, which may increase risk for heart attack or stroke.
   - Increased number of red blood cells (increased hemoglobin), which may cause headache, dizziness, heart attack, confusion, visual disturbances, or stroke.
   - Acne
   - Increased risk of the following:
     Heart disease and stroke;
     High blood pressure;
     Liver inflammation;
   - Increased or decreased sex drive and sexual functioning;
   - Psychiatric symptoms such as depression and suicidal feelings; anxiety; psychosis (disorganization and loss of touch with reality), and worsening of pre-existing psychiatric illnesses.

B. Some side effects from hormones are irreversible and can cause death.

C. The risks for some of the above adverse events may be INCREASED by
   - Pre-existing medical conditions
   - Pre-existing psychiatric conditions
   - Cigarette smoking
   - Alcohol use
D. Irreversible body changes (potential increases with length of time on hormones) resulting from hormone therapy may include, but are not limited to:

- Deepening of voice,
- Development of facial & body hair,
- Fat redistribution,
- Genital changes (i.e. enlargement of clitoris & labia, vaginal dryness),
- Increased bone density,
- Infertility,
- Male pattern baldness.

E. My signature below constitutes my acknowledgement of the following:

- My Callen-Lorde medical provider has discussed with me the nature and purpose of hormone therapy; the benefits and risks, including the risk that hormone therapy may not accomplish the desired objective; the possible or likely consequences of hormone therapy; and all feasible alternative diagnostic or treatment options.
- I have read and understand the above information regarding the hormone therapy, and accept the risks involved.
- I have met with a Callen-Lorde Provider for education and support regarding hormone therapy.
- I have received a list of community services and resources for people of transgender experience.
- I have had sufficient opportunity to discuss my condition and treatment with the medical provider, nursing staff, and/or other Callen-Lorde staff, and all of my questions have been answered to my satisfaction.
- I believe I have adequate knowledge on which to base an informed consent to the provision of hormone therapy.
- I authorize and give my informed consent to the provision of hormone therapy.

__________________________________________  ______________________
Signature of Client                                Date

__________________________________________
Legal Name of Client (Printed)

__________________________________________  ______________________
Signature of Witness                               Date

__________________________________________
Name of Witness (Printed)

My medical provider is
Callen-Lorde Protocols for the Provision of Cross-Gender Hormone Therapy

Appendix 2

Transgender Health Resource Guide

NYC-Metro Area Transgender and Gender Non-Conforming (TGNC) Community Resources

Below is the link to Callen-Lorde’s resource guide to community organizations and social and supportive services in the NYC-Metro area for TGNC people.

http://callen-lorde.org/pdf/NYC%20Metro%20TGNC%20Resources.pdf
Callen-Lorde Protocols for the Provision of Cross-Gender Hormone Therapy

Appendix 3

Managing Co-morbidities

1. **Active Psychosis**

   Active psychosis is defined here as loss of contact with reality and a decline in general functioning. If a patient presents with active psychosis that is not centered on their gender identity, the patient should be stabilized by psychotropic medications and/or psychotherapy before beginning hormone therapy. A mental health professional with experience in transgender care must confirm the patient’s ability to consent to treatment at the time hormone therapy is initiated. The treatment plan can be determined by the patient’s medical and mental health providers and the patient. When setting the plan of transgender care including for hormone therapy, medical and mental health providers should also consider the impact of the psychological distress associated with a delay of hormone treatment.

2. **Cigarette Smoking**

   While patients who smoke can begin hormone therapy, it should be made clear that for both women and men of transgender experience, smoking while taking hormones may increase the risk of adverse events. For patients on feminizing hormones, cigarette smoking may increase the likelihood of thrombotic events. For patients on masculinizing hormones, it may increase the potential for coronary artery disease. At every visit, the provider should actively engage the patient in negotiation around smoking cessation. Aspirin therapy may be considered.

3. **Coronary Artery Disease**

   Hormone therapy is not contraindicated in the presence of stable coronary artery disease. The provider should intervene to decrease all other risk factors for coronary artery disease. Transdermal estrogen therapy may be preferred over alternate routes of administration.

4. **Dementia**

   Dementia is not an absolute contraindication to hormone therapy. Hormone therapy can be provided to patients who are able to give informed consent. For patients who cannot give consent, provision of hormone therapy should be decided on a case-by-case basis, e.g. involvement of guardian. Education of all caretakers is an important component of the treatment plan.

5. **History of Deep Venous Thrombosis, Pulmonary Embolism or Embolic Stroke**

   Some forms of estrogen may increase future risk of venous thromboembolism (VTE). In one study only ethinyl estradiol was liked to VTE among transgender women. Use of transdermal estrogens may be preferred. Patients should be aware of the potential increased risk of complications as part of the informed consent process.
6. **Homicidal/Suicidal Ideation/Attempts**

Patients presenting with active suicidal or homicidal ideation or attempts should be engaged in mental health care. A mental health professional with experience in transgender care should be involved in the treatment plan. When setting the plan of transgender care including a time frame for hormone therapy, medical and mental health providers should also consider the impact of the psychological distress associated with a delay of hormone treatment.

7. **Liver Disease**

If the patient has a self-limited hepatic infection, such as acute Hepatitis A or B, initiation of hormone therapy should be delayed until the patient is in the convalescent stage and transaminases have returned to normal. If the patient has chronic hepatitis for which treatment is available, such as Hepatitis C, treatment should be pursued. Patients with chronic hepatitis should be closely monitored during initiation of hormones or hormone dosage change. If transaminases (ALT) increases 2 times above baseline then consultation with hepatologist is advised. Transdermal/parenteral hormones are preferred to oral administration. For all patients with chronic liver disease, the primary care provider should minimize the risk of further liver injury with appropriate immunizations and behavioral interventions.

8. **Pituitary Adenoma**

If the patient has a history of pituitary adenoma, estrogen therapy should be delayed until the patient has had a full evaluation and clearance from an endocrinologist.

9. **Uncontrolled Diabetes**

There is no clear evidence on the relationship between hormone therapy and glycemic control in diabetics. Diabetes should be managed independent of hormone therapy.

10. **Uncontrolled Hypertension**

Hypertension should be managed independently of hormone therapy. Spironolactone is the preferred anti-androgen.

11. **Substance Use**

Substance use is not a contraindication to hormone therapy. In some cases, hormone therapy may increase the likelihood of patients engaging in treatment for substance use. When making referrals it is important to ensure that the program will affirm the patient’s gender identity.

12. **HIV Infection**

HIV disease is not a contraindication to hormone therapy. In fact, hormone therapy may improve engagement and retention in care.

There are no specific data on interactions between the doses of estrogens commonly used in feminizing regimens and antiretroviral regimens. Most of the available data is based on studies with oral contraceptives (ethinyl estradiol). Metabolism of estrogens occurs via the cytochrome P450 enzyme system, thus potential drug-drug interactions may exist between estrogens and Non-nucleoside reverse
transcriptase inhibitors (NNRTIs) and the Protease inhibitors (PIs). Most boosted PI's decrease ethinyl estradiol levels. The effects of Non-nucleosides vary, e.g. nevirapine decreases estrogen levels, etravirine and rilpivirine increase ethinyl estradiol levels, whereas efavirenz appears to have no effect on estrogen levels. There are no known drug-drug interactions between ethinyl estradiol and NRTIs / NtRTIs / integrase inhibitors / CCR5 antagonists/fusion inhibitors. DHHS recommends that oral contraceptives and amprenavir (or fosamprenavir) not be co-administered due to decrease in amprenavir serum concentrations; therefore, we recommend avoiding the use of amprenavir (Agenerase) and fosamprenavir (Lexiva) with estrogens.

Consider monitoring estradiol levels when initiating or changing anti-retroviral therapy.
1. **Anemia**

   If a patient develops hemoglobin less than 11gm/dL and the patient is taking flutamide, the flutamide should be discontinued and the hemoglobin should be rechecked one month later. If it remains abnormal, a full anemia work-up should be initiated.

2. **Erythrocytosis**

   Testosterone may result in an elevated hematocrit due to increased erythropoiesis. It is important to rule out other causes of erythrocytosis such as polycythemia vera. Hematocrit should be maintained at less than 45%. If the hematocrit increases above 52%, measures include initiation of phlebotomy, decreasing the dose of intramuscular testosterone, or switching to transdermal testosterone gel.

3. **Elevated Prolactin Level**

   If a patient has a prolactin level between 20 and 100ng/mL, the patient should be followed with history (focusing on visual field deficits) and physical exam (blood pressure, fundoscopic exam and gross visual field assessment). For prolactin levels 40-100ng/mL, reduce estrogen levels by half and recheck in 6-8 weeks. Continue hormones at the lower dose if prolactin levels remain under 40ng/mL. If a patient has a prolactin level over 100ng/mL, hormones should be discontinued, and the level should be rechecked. If it remains over 100ng/mL, an MRI of the pituitary should be obtained to rule out pituitary adenoma. If the MRI is normal, hormones can be restarted at a lower dose, and prolactin level should be followed. If it continues to rise, or if the MRI is abnormal, the patient should be referred to an endocrinologist.

   **Guidelines for Elevated Prolactin Level**

<table>
<thead>
<tr>
<th>LEVEL (ng/mL)</th>
<th>ACTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 25</td>
<td>Continue to monitor per protocol.</td>
</tr>
<tr>
<td>25-40</td>
<td>Ask patient about outside sources of estrogen and continue to monitor per protocol.</td>
</tr>
<tr>
<td>40-100</td>
<td>Decrease estrogen doses by half and recheck in 6-8 weeks</td>
</tr>
<tr>
<td>&gt;100</td>
<td>Stop estrogen and recheck in 6-8 weeks. If level remains high, MRI pituitary. If level decreases, restart estrogen at lower dose.</td>
</tr>
</tbody>
</table>

   Adapted from Whitman Walker Transgender Protocols 2010

4. **Elevated Transaminases (LFTs)**

   Elevated Transaminases should be defined as AST/ALT greater than three times the upper limit of normal or twice baseline if the patient has chronically elevated liver enzymes. If transaminases are elevated, hormone therapy should be discontinued while a work up is initiated. The initial evaluation should include a careful history of the patient’s symptoms and use of alcohol, hormones that were not prescribed by the provider, other prescription, over the counter and herbal medications, and other
potential hepatotoxic agents* as well as evaluation for acute and chronic hepatitis. If acute viral hepatitis is diagnosed, hormone therapy should be withheld until the patient is in the convalescent stage and transaminases have returned to normal. If no identifiable cause is revealed, transaminases should be rechecked two months after stopping hormone therapy. If they have returned to normal, the provider can conclude that the hormones were causing the liver inflammation, and they can be restarted and maintained at a lower dose, or a different medication can be tried. If transaminases remain abnormal, the patient should be referred for evaluation by a gastroenterologist.

* Medications to consider include acetaminophen, phenytoin, valproic acid, sulfonamides, nitrofurantoin, isoniazid, rifampin, niacin and alpha-methyldopa.
# TABLES OF MEDICATIONS AND THEIR EFFECTS

## Table 1: “Feminizing” Regimens

<table>
<thead>
<tr>
<th>MEDICATION &amp; STRENGTH</th>
<th>INITIAL DOSE</th>
<th>MAXIMUM DOSE</th>
<th>INTENDED EFFECTS</th>
<th>POSSIBLE SIDE EFFECTS</th>
<th>LABS TO MONITOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol Cypionate 5mg/ml (Depo-Estradiol)</td>
<td>2.5mg (0.5cc) Intramuscularly Every two weeks</td>
<td>5mg (1cc) Intramuscularly Every two weeks</td>
<td>Hypertrophy of breasts Impotence Redistribution of fat Testicular atrophy Reversal of androgenic hair loss Loss of body hair Softening of skin</td>
<td>Cerebrovascular Accident (Stroke) Deep Vein Thrombosis Pulmonary Embolism Depression Gallbladder disease Gastrointestinal upset Headache Hepatitis Hypercalcemia Hyperlipidemia Hypertension Impotence Loss of libido Mood changes Pituitary adenoma Sterilization</td>
<td>Lipids Liver enzymes Prolactin</td>
</tr>
<tr>
<td>Estradiol Valerate 20mg/ml or 40mg/ml (Delestrogen)</td>
<td>10-20mg Intramuscularly Every two weeks</td>
<td>20-40mg Intramuscularly Every two weeks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estradiol (Estrace)</td>
<td>1 mg Orally, twice daily</td>
<td>2 mg Orally, twice daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estradiol transdermal Patch 0.1mg (Vivelle-Dot)</td>
<td>1 patch Topically, twice weekly</td>
<td>2 patches Topically, twice weekly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conjugated estrogens 1.25mg/2.5mg (Premarin)</td>
<td>1.25 mg Orally, twice daily</td>
<td>2.5mg Orally, twice daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medroxyprogesterone [\text{acetate, e.g. Provera}]</td>
<td>5mg orally, once daily</td>
<td>10mg orally once daily</td>
<td>Hypertrophy of breasts (disputed)</td>
<td>Weight gain, dyslipidemia, depression, dizziness In combination with estrogen: DVT: pulmonary embolism, stroke, myocardial infarction, Invasive breast cancer (in cisgender women)</td>
<td>Lipids, CBC, LFTs</td>
</tr>
<tr>
<td>Depo-medroxyprogesterone, e.g. DepoProvera®</td>
<td>150 mg Intramuscularly, every 3 months</td>
<td>150 mg Intramuscularly, every 3 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Micronized progesterone (Prometrium®)</td>
<td>100mg orally, Once daily</td>
<td>200 mg orally, Once daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEDICATION</td>
<td>INITIAL DOSE</td>
<td>MAXIMUM DOSE</td>
<td>INTENDED EFFECTS</td>
<td>POSSIBLE SIDE EFFECTS</td>
<td>LABS TO MONITOR</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------------------</td>
<td>--------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>75-100 mg Orally in divided daily dosing</td>
<td>200-400mg Orally in divided daily dosing</td>
<td>Decrease of androgenic alopecia, Impotence, Thinning and decrease of body and facial hair, Hypertrophy of breasts</td>
<td>Ataxia, Gastric ulcer, Gastronintestinal upset, Headache, Hirsutism, Hyperkalemia, Hyponatremia, Hypotension, Mood Changes</td>
<td>Electrolytes</td>
</tr>
<tr>
<td>(Aldactone) 25mg, 50mg, 100mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flutamide</td>
<td>125 mg Orally, twice daily</td>
<td>125 mg Orally, twice daily</td>
<td></td>
<td>Anemia, Gastrointestinal upset, Hot flashes, Impotence, Loss of libido, Mood Changes, Rash, Testosterone elevation*</td>
<td>Complete Blood count, Liver enzymes</td>
</tr>
<tr>
<td>(Eulexin) 125mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finasteride</td>
<td>1mg Orally, once daily</td>
<td>5mg Orally, once daily</td>
<td>Decrease of androgenic alopecia</td>
<td>Decreased libido, Impotence, Mood Changes, Testosterone elevation*</td>
<td>Liver enzymes</td>
</tr>
<tr>
<td>(Proscar) 5mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Propecia) 1mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dutasteride</td>
<td>0.5mg Orally, once daily</td>
<td>0.5mg Orally, once daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Avodart) 0.5mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyproterone acetate</td>
<td>50mg</td>
<td>150mg</td>
<td>Decrease of androgenic alopecia, Impotence, Thinning and decrease of body and facial hair, Hypertrophy of breasts</td>
<td>Thromboembolic events, Hepatic toxicity, Benign and malignant liver tumors, Intraabdominal hemorrhage, Meningioma, Anemia, Depression</td>
<td>Complete Blood count, Liver enzymes, Electrolytes</td>
</tr>
<tr>
<td>(Androcur*)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Dutasteride, finasteride and flutamide may cause a transient elevation in testosterone that is probably not clinically significant
Choosing an Anti-Androgen

Spironolactone should be the first line Anti-Androgen as it is both safe and cost effective. It should be avoided only in patients who have a history of hyperkalemia, low blood pressure, or renal failure. In the presence of these, Flutamide can be used. Finasteride and dutasteride are weaker anti-androgens (dihydrotestosterone blockers) that may be used alone if other anti-androgens are contraindicated or not tolerated. They can also be used in conjunction with the anti-androgens if the patient is experiencing androgenic alopecia.

Note: Anti-Androgens are not needed in transgender women who have undergone orchiectomy.
<table>
<thead>
<tr>
<th>MEDICATION</th>
<th>INITIAL DOSE</th>
<th>MAXIMUM DOSE</th>
<th>INTENDED EFFECTS</th>
<th>POSSIBLE SIDE EFFECTS</th>
<th>LABS TO DRAW</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone Cypionate</td>
<td>100 mg Intramuscularly, every two weeks</td>
<td>200 mg Intramuscularly, every two weeks</td>
<td>Clitoral hypertrophy</td>
<td>Acne</td>
<td>Complete Blood Count</td>
</tr>
<tr>
<td>100mg/ml Or 200mg/ml</td>
<td>Same dose for post-oophorectomy men</td>
<td>Same dose for post-oophorectomy men</td>
<td>Growth of facial and body hair</td>
<td>Amenorrhea</td>
<td>Lipids</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Increase in muscle mass and definition</td>
<td>Androgenic alopecia</td>
<td>Liver enzymes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Increase of androgenic alopecia</td>
<td>Depression</td>
<td>Prolactin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lowering of vocal pitch</td>
<td>Gastrointestinal upset</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Headache</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hepatitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hyperlipidemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hypertension</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mood Changes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Polycythemia</td>
<td></td>
</tr>
<tr>
<td>Testosterone Enanthate*</td>
<td>100 mg Intramuscularly, every two weeks</td>
<td>200 mg Intramuscularly, every two weeks</td>
<td>Clitoral hypertrophy</td>
<td>Acne</td>
<td></td>
</tr>
<tr>
<td>100mg/ml Or 200mg/ml</td>
<td>Same dose for post-oophorectomy men</td>
<td>Same dose for post-oophorectomy men</td>
<td>Growth of facial and body hair</td>
<td>Amenorrhea</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Increase in muscle mass and definition</td>
<td>Androgenic alopecia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Increase of androgenic alopecia</td>
<td>Depression</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lowering of vocal pitch</td>
<td>Gastrointestinal upset</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Headache</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hepatitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hyperlipidemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hypertension</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mood Changes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Polycythemia</td>
<td></td>
</tr>
<tr>
<td>Testosterone gel (Testim or Androgel)</td>
<td>2.5mg Topically daily</td>
<td>5-10 mg Topically daily</td>
<td>As above</td>
<td>Local irritation</td>
<td></td>
</tr>
<tr>
<td>1mg/g (1%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testosterone patch (Androderm)</td>
<td>2.5mg Patch daily</td>
<td>5mg Patch daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.5mg or 5mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Testosterone Enanthate is supplied only in 5cc vials. Therefore, it is not listed as an option in the parts of the protocol that require prescribing less than 5cc. If a patient is hormone experienced and already taking Testosterone Enanthate, this can be substituted for Testosterone Cypionate.
Table 4A: Masculinizing Effects in FTM Clients Receiving Testosterone

<table>
<thead>
<tr>
<th>EFFECT</th>
<th>ONSET (MONTHS)</th>
<th>MAXIMUM (YEARS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin oiliness/acne</td>
<td>1-6</td>
<td>1-2</td>
</tr>
<tr>
<td>Facial hair</td>
<td>6-12</td>
<td>4-5</td>
</tr>
<tr>
<td>Androgenic hair loss (scalp)</td>
<td>6-12</td>
<td></td>
</tr>
<tr>
<td>Increased muscle mass</td>
<td>6-12</td>
<td>2-5</td>
</tr>
<tr>
<td>Fat redistribution</td>
<td>1-6</td>
<td>2-5</td>
</tr>
<tr>
<td>Cessation of menses</td>
<td>2-6</td>
<td></td>
</tr>
<tr>
<td>Clitoral enlargement</td>
<td>3-6</td>
<td>1-2</td>
</tr>
<tr>
<td>Vaginal atrophy</td>
<td>3-6</td>
<td>1-2</td>
</tr>
<tr>
<td>Deepening of voice</td>
<td>6-12</td>
<td>1-2</td>
</tr>
</tbody>
</table>

Table 4B: Feminizing Effects in MTF Clients Receiving Estrogen and Anti-Androgen

<table>
<thead>
<tr>
<th>EFFECT</th>
<th>ONSET (MONTHS)</th>
<th>MAXIMUM (YEARS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decrease in muscle mass and strength</td>
<td>3-6</td>
<td>1-2</td>
</tr>
<tr>
<td>Softening of skin</td>
<td>3-6</td>
<td>unknown</td>
</tr>
<tr>
<td>Decreased erections</td>
<td>1-3</td>
<td>3-6</td>
</tr>
<tr>
<td>Breast growth</td>
<td>3-6</td>
<td>2-3</td>
</tr>
<tr>
<td>Decreased testicular volume</td>
<td>3-6</td>
<td>2-3</td>
</tr>
<tr>
<td>Decreased sperm production</td>
<td>Unknown</td>
<td>&gt;3</td>
</tr>
<tr>
<td>Voice changes</td>
<td>none</td>
<td></td>
</tr>
</tbody>
</table>

Adapted from The Endocrine Society Clinical Practice Guidelines, 2009
Transgender Health Services

We would like to thank our colleagues for their support, assistance and expertise:

The 2012 Revision of the Callen-Lorde Protocols was made possible through a grant from the Paul Rapoport Foundation.